000650 仁和药业
2024/06 - 中期
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入2,364,333-11.84%5,032,1465,153,2154,935,7554,277,798
减:营业总成本1,915,744-11.90%4,045,0634,208,2373,952,0083,474,607
    其中:营业成本1,457,431-12.50%3,164,0923,266,2773,061,4152,599,873
               财务费用(8,750)-26.21%(24,925)(23,065)(55,244)(8,790)
               资产减值损失(399)--(223,111)(68,739)(5,066)(2,558)
公允价值变动收益(953)-155.63%16,82822,115(26)(118)
投资收益9,344-30.79%59,26146,31431,47571,446
    其中:对联营企业和合营企业的投资收益(1,976)--(915)1,80366,196
营业利润544,628-3.13%898,635953,2631,036,928881,651
利润总额541,703-3.46%898,860953,5401,034,418868,786
减:所得税费用128,997-2.92%269,450241,997234,545194,491
净利润412,706-3.63%629,410711,542799,874674,295
减:非控股权益75,5305.32%62,153137,112134,84994,114
股东净利润337,176-5.43%567,257574,430665,025580,180

市场价值指针
每股收益 (元) *0.241-5.42%0.4100.4100.4800.460
每股派息 (元) *----0.2000.2000.1000.200
每股净资产 (元) *4.4958.17%4.2814.1013.7773.624
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容